GHB (gamma-hydroxybutyrate) has one of the narrowest therapeutic windows of any recreational drug: the dose that produces euphoria is typically only 2 to 3 times lower than the dose that produces unconsciousness, respiratory depression, and potential death. This margin shrinks further when GHB is combined with alcohol or other CNS depressants, a common pattern in club settings. GHB withdrawal is also uniquely dangerous among recreational drugs, producing a syndrome that can include seizures, delirium, and autonomic instability requiring ICU-level medical management.
The Pharmacology of an Unforgiving Drug
“GHB is the substance that frightens emergency physicians and addiction specialists more than almost any other club drug, and for good reason,” says Dr. Ponlawat Pitsuwan, Physician at Phuket Island Rehab. “The pharmacological margin between the recreational dose and the lethal dose is razor-thin, the withdrawal syndrome is medically dangerous in a way that surprises people who think of GHB as a ‘party drug,’ and the speed at which physical dependence develops catches users off guard. I have seen clients progress from weekend club use to round-the-clock dosing within three to four months, a timeline that is faster than almost any other substance.”
GHB is an endogenous substance, meaning it occurs naturally in the human brain at low concentrations, where it functions as a neuromodulator at both the GHB receptor and the GABA-B receptor. At recreational doses (typically 1 to 3 grams orally), exogenous GHB overwhelms the natural regulatory mechanisms and produces effects primarily through GABA-B receptor agonism: euphoria, sociability, disinhibition, enhanced tactile sensation, and a sense of emotional warmth that users compare to a combination of alcohol and MDMA.
The steep dose-response curve is what makes GHB uniquely dangerous. At 1 to 2 grams, the user experiences mild euphoria and relaxation. At 2 to 3 grams, effects intensify to strong euphoria and disinhibition. At 3 to 4 grams, sedation becomes dominant, motor control is severely impaired, and nausea is common. At 4 to 5 grams, loss of consciousness occurs. Above 5 grams, or at lower doses combined with alcohol, respiratory depression can become life-threatening. The difference between “a great night” and unconsciousness can be a matter of a single gram, and the variability of illicit GHB concentration (often sold as an unmarked liquid of unknown strength) makes accurate dosing impossible.
GHB Overdose: Recognition and Risk
| Dose Level | Typical Effects | Risk Level | Action Required |
|---|---|---|---|
| 1 to 2g (light) | Mild euphoria, relaxation, sociability | Low | Monitoring only |
| 2 to 3g (moderate) | Strong euphoria, motor impairment, nausea | Moderate | Do not combine with other depressants |
| 3 to 5g (high) | Heavy sedation, unconsciousness, vomiting | High | Recovery position, monitor breathing, call emergency services |
| 5g+ or any dose + alcohol | Deep coma, respiratory depression, aspiration risk | Critical | Emergency medical intervention, possible intubation |
| Any dose + opioids | Synergistic respiratory depression | Life-threatening | Immediate emergency intervention |
The combination of GHB with alcohol is particularly lethal because both substances act on the GABAergic system but through different receptor subtypes (GHB primarily at GABA-B, alcohol primarily at GABA-A), producing additive CNS depression that exceeds what either substance would produce alone at those doses. A dose of GHB that might be manageable on its own can produce respiratory failure in combination with even moderate alcohol intake. This is especially relevant in club settings where GHB is frequently consumed alongside alcohol.
GHB overdose presents with a characteristic pattern: sudden onset of deep sedation or unconsciousness (often described as “going under” within minutes), bradycardia (slow heart rate), respiratory depression, hypothermia, and the risk of vomiting while unconscious (aspiration). Unlike opioid overdose, there is no specific antagonist for GHB; naloxone does not reverse GHB-induced respiratory depression. Management is supportive: maintaining airway patency, providing ventilatory support if needed, and monitoring until the drug is metabolised (typically 4 to 6 hours).
GHB Dependence: Faster Than You Expect
GHB’s short duration of action (2 to 4 hours) drives a frequency of dosing that rapidly produces physical dependence. Users who progress to daily use typically dose every 2 to 4 hours, including through the night (setting alarms to redose during sleep), because the withdrawal symptoms that emerge between doses are intensely unpleasant: anxiety, tremor, insomnia, and tachycardia. This round-the-clock dosing pattern can establish itself within weeks to months of regular use, far faster than dependence develops with most other recreational substances.
The speed of dependence development often takes users by surprise. A person who begins using GHB recreationally on weekends may progress to twice-weekly, then every-other-day, then daily use within a matter of months, driven not by escalating pleasure-seeking but by the emergence of inter-dose withdrawal symptoms that make abstinence progressively more uncomfortable. By the time physical dependence is established, the person is dosing multiple times per day and experiencing withdrawal symptoms within 2 to 6 hours of their last dose.
GHB Withdrawal: A Medical Emergency
GHB withdrawal is one of the most medically dangerous withdrawal syndromes of any recreational drug, comparable in severity to alcohol and benzodiazepine withdrawal and potentially exceeding them in acute intensity. Withdrawal can produce seizures (including status epilepticus), autonomic instability, delirium, psychosis, and rhabdomyolysis (muscle breakdown that can cause kidney failure). Deaths have been documented from unsupervised GHB withdrawal.
The withdrawal timeline is compressed compared to alcohol: symptoms begin within 1 to 6 hours of the last dose (reflecting GHB’s short half-life), peak at 24 to 72 hours, and typically resolve within 5 to 15 days. However, the acute phase can be extreme, with agitation, hallucinations, and autonomic instability requiring ICU admission and sedation with benzodiazepines or, in refractory cases, barbiturates or propofol. The benzodiazepine doses required to manage GHB withdrawal often exceed those used for alcohol withdrawal because GHB withdrawal involves GABA-B receptor dysfunction that benzodiazepines (which target GABA-A) only partially address.
This withdrawal severity is why GHB cessation must never be attempted without medical supervision. The person who has been dosing every 2 to 4 hours for weeks or months cannot simply “stop” without risking life-threatening complications. Medical detoxification programmes experienced with GHB withdrawal provide the monitoring and pharmacological support needed for safe cessation. Residential treatment ensures continuous medical oversight during the withdrawal period and provides the therapeutic environment for recovery once stabilisation is achieved.
GHB in the Club and Chemsex Context
GHB occupies a specific niche within club drug culture and, increasingly, within chemsex contexts (the use of drugs specifically to enhance sexual activity). In chemsex settings, GHB is valued for its disinhibiting and euphoric properties, and its short duration allows users to time doses around sexual activity. The combination of GHB with methamphetamine and mephedrone (the “chemsex triad”) carries compounded risks: cardiovascular stress from stimulants, respiratory depression from GHB, and extreme risk-taking behaviour under the combined influence.
The chemsex context adds layers of clinical complexity to GHB treatment. Sexual health concerns (HIV/STI risk from unprotected sex), trauma from sexual experiences that occurred under chemical influence, and the social networks built around chemsex practice all require attention within the treatment framework. Substance use treatment that addresses the specific context of use, rather than treating GHB in isolation from the behaviours and communities surrounding it, produces more meaningful and sustained recovery outcomes.
When Substance Use Has Become More Than Occasional
If you are using GHB more than once per week, if you have begun dosing during the day rather than only at night, if you notice anxiety or tremor in the hours between doses, or if you set alarms to dose during the night, physical dependence has likely developed and cessation without medical supervision could be dangerous.
Do not attempt to stop GHB abruptly. The withdrawal syndrome from established GHB dependence is medically dangerous and can produce seizures, delirium, and other life-threatening complications. GHB addiction treatment begins with medically supervised detoxification using benzodiazepine or baclofen (a GABA-B agonist that more directly addresses GHB withdrawal) taper protocols. Following detoxification, anxiety treatment and depression treatment address the mood disturbances that commonly emerge during post-withdrawal recovery. Polydrug patterns involving GHB alongside stimulants or alcohol require integrated treatment approaches.
Summary
GHB’s narrow margin between recreational and lethal doses, combined with its rapid development of physical dependence and its medically dangerous withdrawal syndrome, makes it one of the highest-risk substances in the recreational drug landscape. The drug’s steep dose-response curve, the variability of illicit preparations, and its synergistic lethality with alcohol and opioids create a continuous overdose risk during active use. The withdrawal syndrome, involving seizures, delirium, and autonomic instability, demands medical supervision for safe cessation and places GHB in the same medical urgency category as alcohol and benzodiazepine withdrawal.
“GHB dependency develops faster and announces itself later than almost any other substance I treat,” concludes Dr. Ponlawat Pitsuwan. “By the time a person recognises they are dependent, they are typically dosing every few hours around the clock, and stopping without medical support is genuinely dangerous. The message I need people to hear is clear: if you are using GHB regularly, do not try to stop on your own. Medical supervision is not optional for GHB withdrawal. It is a safety requirement. And the sooner you seek it, the shorter and more manageable the withdrawal process will be.”
Frequently Asked Questions
How quickly can you become addicted to GHB?
Physical dependence on GHB can develop within weeks of daily use, significantly faster than most other substances. The short duration of action (2 to 4 hours) means that daily users dose multiple times per day, and the brain rapidly adapts to the constant GABA-B stimulation. Users who progress from weekend to daily use may develop clinically significant dependence within one to three months. The speed of dependence development is one of GHB’s most underappreciated dangers.
Can you die from GHB withdrawal?
Yes. GHB withdrawal can produce seizures (including prolonged seizures or status epilepticus), severe autonomic instability, delirium with extreme agitation, and rhabdomyolysis, any of which can be fatal without medical management. Deaths from GHB withdrawal have been documented in medical literature. This is why GHB cessation in dependent individuals requires medical supervision, ideally in an inpatient or hospital setting where seizure management and intensive monitoring are available.
Why is mixing GHB and alcohol so dangerous?
GHB and alcohol both suppress the central nervous system through GABAergic mechanisms, but at different receptor subtypes (GABA-B and GABA-A respectively). Their combined effect on respiratory centres in the brainstem is additive or even synergistic, meaning the respiratory depression from the combination exceeds what either substance would produce alone at those doses. A dose of GHB that might produce manageable sedation on its own can cause respiratory failure or coma when combined with even moderate alcohol intake. There is no antidote for this combined overdose.
What does GHB overdose look like?
GHB overdose typically presents with sudden, deep unconsciousness (the person “drops” without warning), slow or shallow breathing, slow heart rate, vomiting (dangerous when unconscious due to aspiration risk), muscle twitching or seizure-like movements, and unresponsiveness to stimulation. The person cannot be roused. If someone shows these signs after possible GHB use, place them in the recovery position (on their side to prevent aspiration if they vomit) and call emergency services immediately. Do not leave them unattended.
Is GHB withdrawal worse than heroin withdrawal?
The two withdrawals are qualitatively different. Heroin withdrawal, while extremely uncomfortable (nausea, diarrhoea, muscle pain, insomnia), is generally not life-threatening in otherwise healthy adults. GHB withdrawal can be life-threatening, with seizure risk, delirium, and autonomic instability comparable to severe alcohol or benzodiazepine withdrawal. In terms of medical danger, GHB withdrawal is significantly more hazardous than opioid withdrawal and requires a higher level of medical supervision.
How is GHB withdrawal treated medically?
Medical management of GHB withdrawal typically involves high-dose benzodiazepines (diazepam or lorazepam) to address seizure risk and agitation, with baclofen (a GABA-B agonist) increasingly used as a specific pharmacological substitute that more directly addresses GHB’s receptor target. Severe cases may require ICU admission with barbiturate or propofol sedation for refractory agitation and seizures. The withdrawal is managed over 5 to 15 days with gradual medication tapering as symptoms subside. Ongoing psychiatric assessment addresses the anxiety, insomnia, and depression that commonly follow acute withdrawal.
Sources:
Schep LJ, Knudsen K, Slaughter RJ, et al. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clinical Toxicology, 2012;50(6):458-470.
Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. Canadian Journal of Emergency Medicine, 2008;10(1):69-74.
Busardo FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Current Neuropharmacology, 2015;13(1):47-70.
van Noorden MS, van Dongen LC, Zitman FG, Vergouwen TA. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. General Hospital Psychiatry, 2009;31(4):394-396.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). GHB and GBL Drug Profile. EMCDDA, 2023.
GHB, gamma-hydroxybutyrate, GBL, 1,4-butanediol, GABA-B receptor, dose-response curve, respiratory depression, CNS depressant, GHB overdose, narrow therapeutic window, GHB withdrawal, seizures, delirium, status epilepticus, rhabdomyolysis, autonomic instability, baclofen, benzodiazepine, ICU, chemsex, polydrug use, bradycardia, aspiration risk, GABA-A receptor, endogenous GHB, neuromodulator, physical dependence, round-the-clock dosing, Dr. Ponlawat Pitsuwan, Phuket Island Rehab